CF101: Phase IIa data

In a double-blind Phase IIa trial in 74 RA patients, oral CF101 reduced disease activity. Maximal responses were seen at a twice-daily dose of 1 mg of CF101, with lower responses at 0.1 and 4 mg. At w...